D A Rizzieri

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint Pulmonary sarcoidosis following stem cell transplantation: is it more than a chance occurrence?
    Rajesh Bhagat
    Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Chest 126:642-4. 2004
  2. ncbi request reprint Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma
    Jeffrey Talbot
    Department of Medicine, Division of Medical Oncology and Stem Cell Transplantation, Duke University Medical Center, Durham, NC 27710, USA
    Clin Lymphoma 5:116-22. 2004
  3. ncbi request reprint Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity
    David A Rizzieri
    Department of Medicine, Division of Oncology and Stem Cell Transplantation, Duke University Medical Center, Durham, NC 27710, USA
    Leuk Lymphoma 46:1455-62. 2005
  4. ncbi request reprint Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors
    Liang Piu Koh
    Adult Bone Marrow and Stem Cell Transplantation Program, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 13:1249-67. 2007
  5. ncbi request reprint Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support
    D A Rizzieri
    Duke University Medical Center Marrow and Stem Cell Transplantation Program, Durham, NC 27710, USA
    J Clin Oncol 17:3064-74. 1999
  6. ncbi request reprint Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251
    David A Rizzieri
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 100:1438-48. 2004
  7. ncbi request reprint Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma
    David A Rizzieri
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Blood 104:642-8. 2004
  8. ncbi request reprint Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma
    David A Rizzieri
    Division of Medical Oncology and Transplantation, Duke University Medical Center, and the Duke Oncology Network, Duke University, Durham, North Carolina 27710, USA
    Cancer 100:2408-14. 2004
  9. pmc Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation
    David A Rizzieri
    Duke University Medical Center, Department of Medicine, Division of Cellular Therapy, Durham, North Carloina, 27705, USA
    Biol Blood Marrow Transplant 16:1107-14. 2010
  10. doi request reprint A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies
    David A Rizzieri
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 14:2756-62. 2008

Research Grants

Detail Information

Publications48

  1. ncbi request reprint Pulmonary sarcoidosis following stem cell transplantation: is it more than a chance occurrence?
    Rajesh Bhagat
    Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Chest 126:642-4. 2004
    ..We suggest that pulmonary sarcoidosis may develop following either autologous or allogeneic HSCT, and the prevalence may be 10-fold higher than that of the normal population...
  2. ncbi request reprint Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma
    Jeffrey Talbot
    Department of Medicine, Division of Medical Oncology and Stem Cell Transplantation, Duke University Medical Center, Durham, NC 27710, USA
    Clin Lymphoma 5:116-22. 2004
    ..The better tolerance, high response rate, and encouraging 2-year survival of this regimen in combination with further dose-dense consolidation in patients with high-risk NHL are encouraging...
  3. ncbi request reprint Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity
    David A Rizzieri
    Department of Medicine, Division of Oncology and Stem Cell Transplantation, Duke University Medical Center, Durham, NC 27710, USA
    Leuk Lymphoma 46:1455-62. 2005
    ..Further, stromal changes correlate with disease response over the course of the patient's disease. This new finding may have implications for the timing of anti-stromally directed therapies...
  4. ncbi request reprint Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors
    Liang Piu Koh
    Adult Bone Marrow and Stem Cell Transplantation Program, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 13:1249-67. 2007
    ..Future challenges remain in determining the safest approach for haploidentical transplant to be performed with minimal risk of GVHD, whereas preserving effective graft-versus-leukemia activity and promoting prompt immune reconstitution...
  5. ncbi request reprint Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support
    D A Rizzieri
    Duke University Medical Center Marrow and Stem Cell Transplantation Program, Durham, NC 27710, USA
    J Clin Oncol 17:3064-74. 1999
    ..We performed a retrospective review to determine predictive and prognostic factors in patients with metastatic breast cancer who received induction therapy, and, if they responded to treatment, high-dose chemotherapy...
  6. ncbi request reprint Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251
    David A Rizzieri
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 100:1438-48. 2004
    ..The objective of the current study was to evaluate the efficacy of intensive chemotherapy with and without cranial radiation for central nervous system (CNS) prophylaxis in adults with Burkitt leukemia or lymphoma...
  7. ncbi request reprint Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma
    David A Rizzieri
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Blood 104:642-8. 2004
    ..These data demonstrate this radiopharmaceutical to be an encouraging agent for the treatment of lymphoma particularly if methods to protect the normal viscera are developed...
  8. ncbi request reprint Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma
    David A Rizzieri
    Division of Medical Oncology and Transplantation, Duke University Medical Center, and the Duke Oncology Network, Duke University, Durham, North Carolina 27710, USA
    Cancer 100:2408-14. 2004
    ..The current study tested this hypothesis by using low-dose, weekly paclitaxel in patients with recurrent or refractory NHL...
  9. pmc Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation
    David A Rizzieri
    Duke University Medical Center, Department of Medicine, Division of Cellular Therapy, Durham, North Carloina, 27705, USA
    Biol Blood Marrow Transplant 16:1107-14. 2010
    ..Future studies must assess whether the improved outcomes are the direct result of the high doses and improved NK cell function or other aspects of immune recovery...
  10. doi request reprint A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies
    David A Rizzieri
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 14:2756-62. 2008
    ..A phase 2 trial was conducted to determine the efficacy and safety of single-agent deforolimus in patients with relapsed or refractory hematologic malignancies...
  11. doi request reprint Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia
    David A Rizzieri
    Department of Medicine, Division of Cellular Therapy, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 115:2922-9. 2009
    ..Response and survival in 96 patients with secondary acute myeloid leukemia (sAML) who received aggressive induction chemotherapy was reviewed...
  12. ncbi request reprint Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution
    David A Rizzieri
    Department of Medicine, Division of Cellular Therapy, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 25:690-7. 2007
    ..To allow a donor to be found for nearly all patients, we have used a nonmyeloablative conditioning regimen in conjunction with stem cells from a related donor with one fully mismatched HLA haplotype...
  13. pmc Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors
    D A Rizzieri
    Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Bone Marrow Transplant 43:327-33. 2009
    ..However, long-term survival still remains poor, primarily because of relapse in these patients...
  14. doi request reprint Phase I study of temozolomide and laromustine (VNP40101M) in patients with relapsed or refractory leukemia
    David Rizzieri
    Division of Cellular Therapy, Duke University, Durham, NC, USA
    Clin Lymphoma Myeloma Leuk 10:211-6. 2010
    ..We conducted a phase I translational study to evaluate the toxicities and estimate the maximum tolerated dose (MTD) of laromustine when administered with temozolomide (TMZ) in patients with hematologic malignancies...
  15. ncbi request reprint Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia
    David A Rizzieri
    Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 20:674-9. 2002
    ..To ascertain the maximum tolerated duration of infusion of gemcitabine at 10 mg/m(2)/min in combination with mitoxantrone at 12 mg/m(2) daily for 3 days in the treatment of acute leukemia...
  16. pmc Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donors
    David A Rizzieri
    Department of Medicine, Division of Cellular Therapy, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Invest 29:56-61. 2011
    ..The primary objective of this pilot study was to evaluate the feasibility of administering IL-2 following a T-cell-depleted nonmyeloablative hematopoietic stem cell transplant...
  17. ncbi request reprint Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen
    D A Rizzieri
    Marrow and Stem Cell Transplantation Program, Duke University Medical Center, Durham, NC 27710, USA
    Blood 98:3486-8. 2001
    ..The patients are in remission and remain 100% donor as assessed by short tandem repeat analysis of the marrow 6 and 12 months following transplantation...
  18. ncbi request reprint Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia
    David A Rizzieri
    Duke University Medical Center, Division of Medical Oncology and Transplantation and the Duke Oncology Consortium, Durham, North Carolina 27710, USA
    Clin Cancer Res 9:663-8. 2003
    ....
  19. pmc Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation
    J Kanda
    Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA
    Bone Marrow Transplant 47:700-5. 2012
    ....
  20. ncbi request reprint Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma
    Adam J Bass
    Division of Medical Oncology and Transplantation, Duke University Medical Center, and the Duke Oncology Consortium, Durham, NC 27710, USA
    J Clin Oncol 20:2995-3000. 2002
    ..To estimate the maximum-tolerated duration of infusion of gemcitabine at 10 mg/m(2)/min in combination with irinotecan at 40 mg/m(2) daily for 3 days in the treatment of relapsed or refractory acute leukemia or lymphoma...
  21. pmc Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment
    J Kanda
    Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA
    Bone Marrow Transplant 48:926-31. 2013
    ..This study suggests that use of CYA for GVHD prophylaxis increases the risk of PES following dual UCB transplantation...
  22. doi request reprint Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy
    Christopher A Crout
    Duke University Medical Center, Department of Medicine, Division of Oncology and Stem Cell Transplantation, Adult Bone Marrow Transplantation Program, Durham, NC, USA
    Cancer Invest 28:654-60. 2010
    ..High responses were noted, though durable remissions were few, indicating non-traditional chemotherapy options are important to investigate in this illness...
  23. ncbi request reprint Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors
    M J Laughlin
    Department of Medicine, Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, OH 44106 5065, USA
    N Engl J Med 344:1815-22. 2001
    ..We studied the use of transplantation of umbilical-cord blood to restore hematopoiesis in adults...
  24. ncbi request reprint Outcomes of a second non-myeloablative allogeneic stem cell transplantation following graft rejection
    B J Byrne
    Division of Stem Cell Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Bone Marrow Transplant 41:39-43. 2008
    ..Two patients are still in recovery phase less than 1 year from the second transplant. Long-term remission is possible and three patients are alive in complete remission...
  25. ncbi request reprint Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia
    Ryan H Shanks
    North Carolina Central University and Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 11:4225-33. 2005
    ..These findings provided a rationale for clinical trials of gemcitabine + fludarabine and gemcitabine + mitoxantrone where responses were observed in heavily pretreated AML patients...
  26. pmc Preemptive dosing of plerixafor given to poor stem cell mobilizers on day 5 of G-CSF administration
    M E Horwitz
    Adult Stem Cell Transplant Program, Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Bone Marrow Transplant 47:1051-5. 2012
    ..In all, 15 out of 20 (75%) patients achieved the primary end point. In conclusion, the decision to administer plerixafor can be delayed until after the peak mobilization response to G-CSF has been fully assessed...
  27. pmc Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors
    D F Chen
    Clinical Transplantation Immunology Laboratory, Department of Pathology, Duke University Medical Center DUMC, Durham, NC 27710, USA
    Bone Marrow Transplant 47:817-23. 2012
    ..These results suggest that the absence of appropriate HLA ligands in the recipient to donor iKIR may induce GVL without aGVHD in myeloid malignancy patients undergoing TCD-RIC transplants...
  28. pmc Haploidentical transplantation for leukemia
    Junya Kanda
    Division of Cellular Therapy, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA
    Curr Oncol Rep 12:292-301. 2010
    ..Success of these new procedures will make haploidentical transplants safer and more effective, further broadening its appeal...
  29. ncbi request reprint Rituximab in lymphocyte predominance Hodgkin's disease: a case series
    Valerie K Ibom
    Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC 27710, USA
    Clin Lymphoma 4:115-8. 2003
    ..5 months after completion of chlorambucil or radiation therapy (range, 3-25 months). Further follow-up is warranted to evaluate response duration and late toxicity of this novel treatment strategy..
  30. doi request reprint Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia
    Arati V Rao
    Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC 27708, USA
    J Clin Oncol 27:5580-6. 2009
    ..To define the biology driving the aggressive nature of acute myeloid leukemia (AML) in elderly patients...
  31. doi request reprint Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia
    Arati V Rao
    Department of Medicine, Divisions of Medical Oncology, Pharmacology, and Cellular Therapy, Duke University Medical Center, Durham, NC 27710, USA
    Leuk Lymphoma 49:1523-9. 2008
    ..002. However, with MTD dosing this drug ratio is not optimal to produce synergy and future studies using ratiometric dosing are required to confirm these findings...
  32. ncbi request reprint Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens
    Nelson J Chao
    Division of Cellular Therapy BMT, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 10:569-75. 2004
    ..This result provides a basis for further exploring this potentially curative approach to selected patients who lack matched related or unrelated hematopoietic stem cell donors...
  33. pmc Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells
    David J Adams
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Leuk Lymphoma 49:786-97. 2008
    ..The impact of drug sequence and ratio on the interactions argues for incorporation of these parameters into the design of combination chemotherapy regimens...
  34. ncbi request reprint 4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia
    David A Rizzieri
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 9:183-8. 2003
    ..Approaches to minimize stomatitis and protect normal stem cells from the toxicity of 4HC may improve the tolerance and efficacy of this approach...
  35. ncbi request reprint Burkitt lymphoma arising in organ transplant recipients: a clinicopathologic study of five cases
    Jerald Z Gong
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Am J Surg Pathol 27:818-27. 2003
    ..Genotypic and phenotypic aberrations are often present. Rituximab may be an effective alternative to conventional combination chemotherapy in the treatment of a posttransplant Burkitt lymphoma...
  36. ncbi request reprint Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF
    Cristina Gasparetto
    Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC, USA
    Cytokine 18:8-19. 2002
    ..In summary, administration of FL in combination with GM-CSF and G-CSF to patients with breast cancer can mobilize large numbers of immature DCs into PBSC leukapheresis collections...
  37. ncbi request reprint Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantation
    Matthew J Snyder
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Am J Surg Pathol 28:794-800. 2004
    ..All three PTLDs arose 6 to 7 months after NMST and were rapidly fatal. The pathology of the PTLD in all cases was donor origin, EBV positive, diffuse large B-cell lymphoma...
  38. ncbi request reprint Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cells
    Nelson J Chao
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Biol Blood Marrow Transplant 8:249-56. 2002
    ..Moreover, the presence of TREC-positive cells within 1 year suggests that thymic recovery is likewise accelerated in non myeloablative compared to myeloablative regimens...
  39. pmc Radioimmunotherapy for Non-Hodgkin's Lymphoma
    Arati V Rao
    Division of Medical Oncology and Division of Geriatrics, Duke University Medical Center and Durham Veterans Affairs Medical Center, Durham, NC 27710, USA
    Clin Med Res 3:157-65. 2005
    ..It also includes updates on the use of RIT in elderly patients and in patients with significant bone marrow involvement among other recent advances made in this field...
  40. ncbi request reprint Morphologic examination of sequential bone marrow biopsies after nonmyeloablative stem cell transplantation complements molecular studies of donor engraftment
    Anand S Lagoo
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Arch Pathol Lab Med 130:1479-88. 2006
    ..Nonmyeloablative stem cell transplantation (NMSCT) is a mode of immunotherapy increasingly employed in treating hematologic, lymphoid, and solid tumors. Patients are monitored principally by molecular analysis of donor engraftment...
  41. ncbi request reprint Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia
    J Brice Weinberg
    Department of Medicine, Division of Hematology, VA and Duke University Medical Centers, 508 Fulton Street, Durham, North Carolina 27705, USA
    Am J Hematol 82:1063-70. 2007
    ....
  42. ncbi request reprint CD52 expression in mantle cell lymphoma
    Adam J Bass
    Duke University School of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Leuk Lymphoma 43:339-42. 2002
    ..This report demonstrates that tumor samples from patients with mantle cell lymphoma express the CD52 antigen and suggests that CAMPATH-1H should be studied in patients with mantle cell lymphoma...
  43. ncbi request reprint Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia
    Steven L McCune
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Leuk Lymphoma 43:1007-11. 2002
    ..Alemtuzumab is a monoclonal antibody that offers effective treatment for chemotherapy refractory CLL and PLL and is generally well tolerated in the outpatient setting...
  44. doi request reprint Leukemic stem cells: a review
    J A O'Brien
    Department of Medical Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Invest 31:215-20. 2013
    ..Research in mouse models provides several potential therapeutics to target these cells in human patients. Eliminating LSCs should provide an efficient, potentially curative treatment option for leukemia patients...
  45. doi request reprint Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia
    J B Weinberg
    Department of Medicine, Duke University and VA Medical Centers, Durham, NC 27705, USA
    Leukemia 22:2184-92. 2008
    ....
  46. pmc Patterns of microRNA expression characterize stages of human B-cell differentiation
    Jenny Zhang
    Duke Institute for Genome Sciences and Policy, Duke University, Durham, NC 27710, USA
    Blood 113:4586-94. 2009
    ..Thus, our data demonstrate that microRNAs may be important in maintaining the mature B-cell phenotype in normal and malignant B cells...
  47. pmc Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
    Stephanie J Lee
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 112:3500-7. 2008
    ..Acute graft-versus-host disease rates were similar between IM(+) and IM(-) groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT...
  48. ncbi request reprint High-dose cyclophosphamide and etoposide for patients with refractory acute myeloid leukemia: a case series
    Jeffrey Talbot
    Am J Hematol 73:295-6. 2003

Research Grants1

  1. Mentored Patient-Oriented Research Career Development Aw
    David Rizzieri; Fiscal Year: 2004
    ..These results will lead to future improvements in maximizing the anti-tumor effects of allogeneic therapy, hastening immunologic recovery, and minimizing the toxicity of this procedure. ..